|
Post by boytroy88 on May 4, 2017 8:33:52 GMT -5
Wait for a blizzard of negative coverages coming out soon. Yeah...one of the "momentum" stock boards I frequent have one of its prominent members recommending shorting MNKD on any spikes. So unless we have definitive funding coming this spike in SP will not last. OT - Hmmmm...funny haven't seen Sports, Peppy, and the other "morning posters" post this morning.... Looks like they are right on track...already back down to .74
|
|
|
Post by akemp3000 on May 4, 2017 8:37:47 GMT -5
This is VERY good news but I suspect more is coming. There's a reason MNKD filed a notice with the SEC relating to a potential change of beneficial ownership on April 19th. I'm not making predictions nor is there any public information to substantiate that more news is coming. I simply believe it based on hints that now include this announcement, continued steps to move forward with commercials and sponsoring a TV reality series, management's silence other than sharing they are in a quiet period and that answers to stockholder questions may soon be answered. Bottom line is that teaming up with ONE NOTE, which includes iphone useage for real-time BG monitoring, might just be an epic jump start to the future...IMHO and GLTA
|
|
|
Post by sportsrancho on May 4, 2017 8:39:01 GMT -5
|
|
|
Post by myocat on May 4, 2017 8:43:05 GMT -5
Let's hope this is one of the efforts steering Afrezza to full commercial where SNY dropped the ball.
|
|
|
Post by uvula on May 4, 2017 8:45:53 GMT -5
Come on guys. Yes, this announcement is better than nothing, but just barely. It is a "memorandum of understanding to enter into a collaborative agreement". No details, no money. People here sound like they expect a short squeeze or something. We need much more than this to survive.
This smells to me like the RLS last minute press release right before a company shareholder meeting.
|
|
|
Post by kball on May 4, 2017 8:52:36 GMT -5
Any thoughts on if they announce these little positives strategically a different day than script numbers so as not to be overshadowed negatively by the weeklies?
It was the 2nd thought that came to mind. 1st was hooray, something!
|
|
|
Post by silentknight on May 4, 2017 8:58:35 GMT -5
Any thoughts on if they announce these little positives strategically a different day than script numbers so as not to be overshadowed negatively by the weeklies? It was the 2nd though that came to mind. 1st was hooray, something! Possibly. Any announcement promoting Afrezza is good, but at the end of the day, the ONLY thing that matters is scripts. Without those, they could come out with a collaboration announcement every day and it wouldn't mean squat.
|
|
|
Post by myocat on May 4, 2017 9:00:01 GMT -5
It would be great if they also announce a partnership with other big Pharma for a joint marketing of Afrezza.
|
|
|
Post by dreamboatcruise on May 4, 2017 9:09:12 GMT -5
Yeah...one of the "momentum" stock boards I frequent have one of its prominent members recommending shorting MNKD on any spikes. So unless we have definitive funding coming this spike in SP will not last. OT - Hmmmm...funny haven't seen Sport, Peppy, and the other "morning posters" post this morning.... If you want the "wet blanket" version: (If by wet blanket, you mean positive, but not wetting my pants positive) Nice looking app for tracking and coaching. Very masculine looking meter and lancet. All-you-can-eat strips. The collaboration means that Onedrop will make Afrezza one of the treatments trackable through their app, and they'll look at developing a bluetooth enabled inhaler. I don't think it implies that Afrezza - a prescription-omnly med - gets added to the subscription service. I think just to the app. Positive news but really not revolutionary. Absent any other news, or a financial strategy, an opportunity to sell at a better price maybe or buy puts at a better price. This, then, may serve as an example of 1. reading news as it is rather than as you hope it is 2. determining how markets will react both in the short and longer term 3. acting on it and possibly getting an advantage over those who act less rationally I suspect there will be a short-term pop followed by buying exhaustion after retails run out of cash or interest. 80% of this app is already applicable to any diabetic, regardless of treatment used. I take it as a positive, but not a huge deal. Of course, maybe it could spark a run, esp if followed up with other positive news. If MNKD wanted to make an impact, Afrezza would already be integrated into the app and the Bluehale-based new inhaler would already be submitted for approval. Instead they're still talking about what will happen in the future. But hey - narrative. Another carrot. It would seem odd that Afrezza could be part of a subscription service, but the wording of the announcement that Afrezza is being added as an offering would seem equally odd if they just meant adding Afrezza as a trackable event in the app log. If I'm correct it appears OneDrop is foregoing insurance payment for test strips. That business model wouldn't seem to make sense for a high priced drug like Afrezza. Even if OneDrop accepted the prescriptions, unless they struck deals with tons of different insurance companies they would need to charge patients considerably more than the patient would otherwise pay as a co-pay under their insurance. Does anyone know if my assumption is incorrect about OneDrop's business... are they potentially striking agreements with insurance so that they get some additional payment from a patient's insurance in addition to what the patient pays for the subscription?
|
|
|
Post by derek2 on May 4, 2017 9:13:45 GMT -5
dreamboatcruise I think you're correct about foregoing insurance. From Onedrop's website: That's pretty good for $450 / yr
|
|
|
Post by sweedee79 on May 4, 2017 9:20:43 GMT -5
we need cash... whether that be a partnership or something else... we need cash .. we cant raise scripts without it ..
Yet, I love this news..
|
|
|
Post by ssiegel on May 4, 2017 9:26:46 GMT -5
Does the collaboration cost Mannkind anything? I looked One Drop up on Crunchbase: www.crunchbase.com/organization/onedrop#/entityIt looks like the last financing they got was two years ago for 8 million dollars. That doesn't strike me as sufficient to start a company marketing a new glucometer.
|
|
|
Post by matt on May 4, 2017 9:30:40 GMT -5
Does anyone know if my assumption is incorrect about OneDrop's business... are they potentially striking agreements with insurance so that they get some additional payment from a patient's insurance in addition to what the patient pays for the subscription? That seems to be the case. It looks to me like this is designed to create a link back to the user's physician or insurance company so that somebody at the payor end can proactively get involved if there is a patient that does not have well-controlled blood sugar. If you look at their site they have a OneDrop Professional service, and that is something insurance will pay for if the concept proves out. The subscription fee is more than adequate to cover the cost of test strips as those are largely a commodity these days, especially when purchased in bulk. You will know this is real if insurers start paying for OneDrop Professional and also pick up the monthly subscriptions for patients. Anything that truly helps control blood sugar translates to big cost savings for insurers, so if the insurance companies are not paying for the subscription that suggests the app is a nice looking tool that doesn't create enough savings. This is doubly true because if a large insurer agreed to pay for everything they would be getting big discounts on everything. If a system can't drive savings of $200 or more for a diabetic, then it has limited value, but if it can deliver those savings then the inventor will be a happy man.
|
|
|
Post by madog365 on May 4, 2017 9:37:48 GMT -5
This seems like a very strategic bet on the future of diabetes management.
Mike's quote about becoming the uber of diabetes: "It's time for a change, and I'm personally interested in building an Uber-like model for diabetes management," "Anything we can do to streamline people's access to drugs and makes it easier, is where we need to go." "I'm really looking to streamline this process, make it a seamless integration into a person's life," Castagna says. "When you think of Uber, you just use the app to get a car, and then you get in the car and everything's done all in one place through the app, the payment and even the feedback. That's what we're looking to do as a company, creating a way for patients to interact in a different way than they have."
The partnership with Onedrop seems like a a step in that direction. One drop has their app which is sort of a diabetes social network and is already doing a subscription based service for diabetes supplies - It will be interesting if Afrezza can become a part of that service. I am also imagining the bluetooth inhaler will feed data into the one drop app.
|
|
|
Post by ssiegel on May 4, 2017 9:40:08 GMT -5
Does anyone know if my assumption is incorrect about OneDrop's business... are they potentially striking agreements with insurance so that they get some additional payment from a patient's insurance in addition to what the patient pays for the subscription? That seems to be the case. It looks to me like this is designed to create a link back to the user's physician or insurance company so that somebody at the payor end can proactively get involved if there is a patient that does not have well-controlled blood sugar. If you look at their site they have a OneDrop Professional service, and that is something insurance will pay for if the concept proves out. The subscription fee is more than adequate to cover the cost of test strips as those are largely a commodity these days, especially when purchased in bulk. You will know this is real if insurers start paying for OneDrop Professional and also pick up the monthly subscriptions for patients. Anything that truly helps control blood sugar translates to big cost savings for insurers, so if the insurance companies are not paying for the subscription that suggests the app is a nice looking tool that doesn't create enough savings. This is doubly true because if a large insurer agreed to pay for everything they would be getting big discounts on everything. If a system can't drive savings of $200 or more for a diabetic, then it has limited value, but if it can deliver those savings then the inventor will be a happy man. Run into the same sort of problems as afrezza. Use the meter that the insurer got the best deal for and its free and supplies are covered: www.ibx.com/providers/pharmacy_information/blood_glucose/Otherwise you need prior authorization.
|
|